On 15 February 2019, the Commission received a request from Healthcare Reckitt B.V. for the evaluation by the Authority of the safety and suitability of two products, an infant and follow-on formula, manufactured from a specific protein hydrolysate, the composition of which did not comply with the requirements laid down in point 2.3 of Annex I and in point 2.3 of Annex II to Delegated Regulation (EU) 2016/127.
Recital 3, Regulation (EU) 2026/743
In forcesince 30 Mar 2026